Miller‐Fisher syndrome after COVID‐19: neurochemical markers as an early sign of nervous system involvement. (13th October 2020)

• Record Type: Journal Article
• Authors: Senel, M.; Abu‐Rumeileh, S.; Michel, D.; Garibashvili, T.; Althaus, K.; Kassubek, J.; Otto, M.
• Is Part Of: European journal of neurology. Volume 27:Number 11(2020)
• Page Start: 2378
• Page End: 2380
• Publication Date: 2020-10-13
• Subjects: coronavirus -- COVID‐19 -- Guillain–Barré syndrome -- Miller‐Fisher -- neurofilament light chain -- SARS‐CoV‐2 -- syndrome; Neurology -- Periodicals; Nervous system -- Diseases -- Periodicals; 616.8
• DOI: 10.1111/ene.14473
• Languages: English
• ISSNs: 1351-5101

Abstract

Abstract : Miller‐Fisher syndrome (MFS) is classified as a variant of Guillain–Barré syndrome (GBS), accounting for 5%–25% of all GBS cases. Since the coronavirus disease‐2019 (COVID‐19) outbreak, increasing evidence has been reported of the neurological manifestations of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, affecting both the central and peripheral nervous system. Here we report the clinical course, detailed cerebrospinal fluid (CSF) profile including CSF/blood antibody status, and neurochemical characteristics of a patient with a typical clinical presentation of MFS after a positive SARS‐CoV‐2 infection test.